Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

RenaSci’s Sharon Cheetham awarded BPS Fellowship

Dr Sharon Cheetham, one of the co-founders of the Sygnature Group company RenaSci, has become a Fellow of the British Pharmacological Society (BPS). To be made a Fellow, BPS members must have demonstrated both distinction and peer recognition in pharmacology.

‘I am delighted to be awarded this Fellowship by the British Pharmacological Society, which promotes and advances pharmacology around the world,’ Sharon said. ‘Science is a collaborative endeavour, and I am extremely grateful to the talented colleagues I have worked with over the years.’

Sharon has been a member of the Society since the early days of her PhD in 1984. She is a specialist in CNS disorders, with a PhD from St George’s Hospital Medical School in London. Her industrial career began in 1988 at Boots Pharmaceuticals in Nottingham. This later became BASF Pharma, and she was part of the team there that developed the antiobesity drug sibutramine.

In 2001, along with two colleagues, Rob Jones and David Heal, Sharon founded the CRO RenaSci to offer specialist in vivo pharmacology models and consultancy services to clients. These include models in the areas of abuse and dependence, CNS, obesity, diabetes, NASH and kidney disease.

In 2018, RenaSci became part of the Sygnature Group, after a long-standing collaboration between RenaSci and Sygnature Discovery. ‘This award comes at an exciting time, when we are expanding our metabolic and CNS portfolio,’ Sharon added. ‘I look forward to the future drug discovery successes that this will allow us to achieve.’


Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.